Surrozen designs tissue-specific antibody therapeutics that modulate the Wnt signaling pathway to drive organ and tissue regeneration. Its proprietary platforms — SWEETS (R-spondin‑mimetics) and SWAP (Wnt‑mimetics) — produce molecules that selectively activate or enhance Wnt signaling in target organs. Lead preclinical candidates include SZN-043 (liver‑specific SWEETS) and SZN-1326 (intestine‑specific SWAP), which showed hepatocyte proliferation, improved liver function and reduced fibrosis, and intestinal epithelial regeneration with anti‑inflammatory effects, respectively. The company plans clinical development of these two IND candidates, targeting filing in 2021 (liver) and 2022 (IBD), and intends to continue discovery to expand its pipeline across additional tissues and disease areas. The recent financing provides capital specifically to advance the two IND candidates to the clinic and to support ongoing discovery work. Surrozen is a San Francisco–based biopharmaceutical company led by CEO Craig Parker that discovers and develops novel antibodies for regenerative medicine. The company has developed two proprietary antibody platforms that can function as Wnt or R-spondin mimetics to stimulate cell- and organ-specific tissue regeneration. Proceeds from its recent financing will be used to advance antibody discovery and development programs in liver disease. Surrozen plans to expand its therapeutic platform into additional disease areas where Wnt modulation has therapeutic potential. The company recently secured financing to support these programs and expanded its Board of Directors with the appointment of Anna Berkenblit, MD. Dr. Berkenblit joins from ImmunoGen, where she is Senior Vice President and Chief Medical Officer, and brings prior clinical development experience from H3 Biomedicine and AVEO Oncology. Surrozen is a South San Francisco–based biopharmaceutical company focused on discovering and developing drugs that promote the repair and regeneration of human tissues by harnessing Wnt signaling. The company provides a broad-based drug discovery platform built around surrogate Wnt technology, with the principal invention credited to K. Christopher Garcia. Its scientific leadership and founders include K. Christopher Garcia, Roeland Nusse, Calvin Kuo and senior scientist Claudia Janda, all with strong academic credentials. Surrozen plans to use new financing to implement its drug discovery platform and advance its therapeutic approach. Financially, the company closed a $33M Series A led by The Column Group, which has taken board representation. The company is positioning its surrogate Wnt platform to translate academic discoveries into therapeutic programs.

Total raised

$133M

Funding rounds

3

Latest round

Series C

Latest activity

Jun 2020